"It got to a point where I couldn't walk," he said. "I would get out of my car, and by the time I got to the door, I (would) need a chair," he said.

If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Trials have shown the weekly injection can help people lose a fifth of their ... other vital NHS services and also to test ways of delivering this new generation of weight loss medications." The NICE ...

LANDRUM—The Real Me TRiM Clinic has officially opened its doors in Landrum, marking a new addition to the community’s ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Clinical trials show that around one in ten people are ‘non-responders’. Outside of trials, that figure might be much higher.